Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Fig. 2

a Percentage change in anti-RBD levels between the first and second assessment, stratified by an interval of 30 days. b Percentage change in anti-RBD levels between first and second assessment according to medication group. a The bars show the percentage change in anti-RBD levels stratified by an interval of 30 days for controls (light gray bars) and patients (dark gray bars). b The bars show the percentage change in anti-RBD levels between the first and second assessment in controls (light gray bar) and in patients (dark gray bars) according to medication groups. Bars indicate the lower and upper quartiles. Horizontal lines inside the bars indicate the median. Vertical lines through the bars show the minimum (Q1−1.5×IQR) and maximum value (Q3+1.5×IQR). Dots indicate outliers. MTX mono, methotrexate monotherapy; ILi, Interleukin inhibitors including tocilizumab, ustekinumab, iksekizumab, risankizumab, secukinumab; VED, vedolizumab; JAKi, janus kinase inhibitor; TNFi mono, tumor necrosis factor inhibitor in monotherapy; TNFi comb, tumor necrosis factor inhibitor in combination with metabolite inhibitor(s) or vedolizumab; RTX, rituximab. All groups include patients using prednisolone in doses <10mg/day in combination with other medication

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us